Premium
Do medulloblastoma tumors meet the food and drug administration criteria for anti‐erbB2 therapy with trastuzumab?
Author(s) -
EntzWerle Natacha,
Velasco Valérie,
Neuville Agnès,
Geoerger Birgit,
Mathieu MarieChristine,
Guerin Eric,
Kehrli Pierre,
Gaub MariePierre,
Vassal Gilles,
Grill Jacques
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20908
Subject(s) - medicine , trastuzumab , medulloblastoma , immunohistochemistry , drug , targeted therapy , oncology , cancer , food and drug administration , blood cancer , antibody , disease , breast cancer , cancer research , immunology , pharmacology
Several publications have recently focused on the erbB2 receptor in pediatric medulloblastomas (MBs) and its prognostic consequence. We determined erbB2 expression in 23 MBs at diagnosis. After DNA extraction, quantitative PCR targeting the erbB2 gene was performed and correlated with FISH analysis and immunohistochemistry. The samples were representative of the spectrum of the disease apart from the absence of large cell MBs. Using the tools validated for breast cancers by the FDA, we did not observe any expression or amplification of erbB2 and hence we speculate that MBs are not a good target for treatment with anti‐erbB2 antibodies. Pediatr Blood Cancer 2008;50:163–166. © 2006 Wiley‐Liss, Inc.